Literature DB >> 10644353

Cytotoxic T-lymphocyte responses to a polymorphic Epstein-Barr virus epitope identify healthy carriers with coresident viral strains.

J M Brooks1, D S Croom-Carter, A M Leese, R J Tierney, G Habeshaw, A B Rickinson.   

Abstract

Cytotoxic T-lymphocyte (CTL) responses to Epstein-Barr virus (EBV) tend to focus on a few immunodominant viral epitopes; where these epitope sequences are polymorphic between EBV strains, host CTL specificities should reflect the identity of the resident strain. In studying responses in HLA-B27-positive virus carriers, we identified 2 of 15 individuals who had strong CTL memory to the pan-B27 epitope RRIYDLIEL (RRIY) from nuclear antigen EBNA3C but whose endogenous EBV strain, isolated in vitro, encoded a variant sequence RKIYDLIEL (RKIY) which did not form stable complexes with B27 molecules and which was poorly recognized by RRIY-specific CTLs. To check if such individuals were also carrying an epitope-positive strain (either related to or distinct from the in vitro isolate), we screened DNA from freshly isolated peripheral blood mononuclear cells for amplifiable virus sequences across the EBNA3C epitope, across a different region of EBNA3C with type 1-type 2 sequence divergence, and across a polymorphic region of EBNA1. This showed that one of the unexplained RRIY responders carried two distinct type 1 strains, one with an RKIY and one with an RRIY epitope sequence. The other responder carried an RKIY-positive type 1 strain and a type 2 virus whose epitope sequence of RRIFDLIEL was antigenically cross-reactive with RRIY. Of 15 EBV-seropositive donors analyzed by such assays, 12 appeared to be carrying a single virus strain, one was coinfected with distinct type 1 strains, and two were carrying both type 1 and type 2 viruses. This implies that a small but significant percentage of healthy virus carriers harbor multiple, perhaps sequentially acquired, EBV strains.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10644353      PMCID: PMC111658          DOI: 10.1128/jvi.74.4.1801-1809.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  Expression of B-type Epstein-Barr virus in HIV-infected patients and cardiac transplant recipients.

Authors:  M T Kyaw; L Hurren; L Evans; D J Moss; D A Cooper; E Benson; D Esmore; T B Sculley
Journal:  AIDS Res Hum Retroviruses       Date:  1992-11       Impact factor: 2.205

2.  Antigenic and sequence variation in the C-terminal unique domain of the Epstein-Barr virus nuclear antigen EBNA-1.

Authors:  M N Wrightham; J P Stewart; N J Janjua; S D Pepper; C Sample; C M Rooney; J R Arrand
Journal:  Virology       Date:  1995-04-20       Impact factor: 3.616

Review 3.  MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation.

Authors:  R N Germain
Journal:  Cell       Date:  1994-01-28       Impact factor: 41.582

4.  Heterogeneity within the Epstein-Barr virus nuclear antigen 2 gene in different strains of Epstein-Barr virus.

Authors:  C Aitken; S K Sengupta; C Aedes; D J Moss; T B Sculley
Journal:  J Gen Virol       Date:  1994-01       Impact factor: 3.891

5.  Detection of A-type and B-type Epstein-Barr virus in throat washings and lymphocytes.

Authors:  A Apolloni; T B Sculley
Journal:  Virology       Date:  1994-08-01       Impact factor: 3.616

6.  Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells.

Authors:  A Bertoletti; A Sette; F V Chisari; A Penna; M Levrero; M De Carli; F Fiaccadori; C Ferrari
Journal:  Nature       Date:  1994-06-02       Impact factor: 49.962

7.  EBV strain variation: geographical distribution and relation to disease state.

Authors:  M Abdel-Hamid; J J Chen; N Constantine; M Massoud; N Raab-Traub
Journal:  Virology       Date:  1992-09       Impact factor: 3.616

8.  Changes in the dominant Epstein-Barr virus type during human immunodeficiency virus infection.

Authors:  M Buisson; P Morand; O Genoulaz; M J Bourgeat; M Micoud; J M Seigneurin
Journal:  J Gen Virol       Date:  1994-02       Impact factor: 3.891

9.  Detection of multiple 'Ebnotypes' in individual Epstein-Barr virus carriers following lymphocyte transformation by virus derived from peripheral blood and oropharynx.

Authors:  J W Gratama; M A Oosterveer; W Weimar; K Sintnicolaas; W Sizoo; R L Bolhuis; I Ernberg
Journal:  J Gen Virol       Date:  1994-01       Impact factor: 3.891

10.  T cell responses and virus evolution: loss of HLA A11-restricted CTL epitopes in Epstein-Barr virus isolates from highly A11-positive populations by selective mutation of anchor residues.

Authors:  P O de Campos-Lima; V Levitsky; J Brooks; S P Lee; L F Hu; A B Rickinson; M G Masucci
Journal:  J Exp Med       Date:  1994-04-01       Impact factor: 14.307

View more
  15 in total

1.  Biophysical and mutational analysis of the putative bZIP domain of Epstein-Barr virus EBNA 3C.

Authors:  Michelle J West; Helen M Webb; Alison J Sinclair; Derek N Woolfson
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

2.  Epstein-Barr virus in oral shedding of children with multiple sclerosis.

Authors:  Carmen Yea; Raymond Tellier; Patrick Chong; Garrett Westmacott; Ruth Ann Marrie; Amit Bar-Or; Brenda Banwell
Journal:  Neurology       Date:  2013-09-06       Impact factor: 9.910

3.  Conservation of Epstein-Barr virus cytotoxic T-cell epitopes in posttransplant lymphomas: implications for immune therapy.

Authors:  Qian Tao; Jie Yang; He Huang; Lode J Swinnen; Richard F Ambinder
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

4.  Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses.

Authors:  A Leen; P Meij; I Redchenko; J Middeldorp; E Bloemena; A Rickinson; N Blake
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

5.  HLA-A11-restricted epitope polymorphism among Epstein-Barr virus strains in the highly HLA-A11-positive Chinese population: incidence and immunogenicity of variant epitope sequences.

Authors:  R S Midgley; A I Bell; Q Y Yao; D Croom-Carter; A D Hislop; B M Whitney; A T C Chan; P J Johnson; A B Rickinson
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

6.  Characterization of variants in the promoter of BZLF1 gene of EBV in nonmalignant EBV-associated diseases in Chinese children.

Authors:  Yingkang Jin; Zhengde Xie; Gen Lu; Shuang Yang; Kunling Shen
Journal:  Virol J       Date:  2010-05-10       Impact factor: 4.099

7.  Conserved mutation of Epstein-Barr virus-encoded BamHI-A Rightward Frame-1 (BARF1) gene in Indonesian nasopharyngeal carcinoma.

Authors:  Susanna H Hutajulu; Eveline K Hoebe; Sandra Awm Verkuijlen; Jajah Fachiroh; Bambang Hariwijanto; Sofia M Haryana; Servi Jc Stevens; Astrid E Greijer; Jaap M Middeldorp
Journal:  Infect Agent Cancer       Date:  2010-09-19       Impact factor: 2.965

8.  Epstein-Barr virus latent membrane protein 1 genetic variability in peripheral blood B cells and oropharyngeal fluids.

Authors:  Nicholas Renzette; Mohan Somasundaran; Frank Brewster; James Coderre; Eric R Weiss; Margaret McManus; Thomas Greenough; Barbara Tabak; Manuel Garber; Timothy F Kowalik; Katherine Luzuriaga
Journal:  J Virol       Date:  2014-01-15       Impact factor: 5.103

9.  Multiple Epstein-Barr virus infections in healthy individuals.

Authors:  Dennis M Walling; Abigail L Brown; Wiguins Etienne; Wendy A Keitel; Paul D Ling
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

10.  Maintenance of serum immunoglobulin G antibodies to Epstein-Barr virus (EBV) nuclear antigen 2 in healthy individuals from different age groups in a Japanese population with a high childhood incidence of asymptomatic primary EBV infection.

Authors:  Shizuko Harada; Yoshio Kamata; Yasuyuki Ishii; Hiroyuki Eda; Ryo Kitamura; Maya Obayashi; Sayuri Ito; Fumihiko Ban; Jun Kuranari; Haruhiko Nakajima; Tomoko Kuze; Masao Hayashi; Nobuhiko Okabe; Hidenobu Senpuku; Nobuyuki Miyasaka; Yoshiko Nakamura; Hirokazu Kanegane; Kazuo Yanagi
Journal:  Clin Diagn Lab Immunol       Date:  2004-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.